Q-omics provides the consensus-scored MIR6505 profile across patient tissues and cancer cell-line models. MIR6505 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, MIR6505 is differentially expressed in 3, with the highest sampling consensus in KIRC. Additionally, MIR6505 RNA expression shows 11,857 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight THCA, KIRC, and UVM as cancer lineages where MIR6505 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR6505 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR6505 survival associations across molecular data types. MIR6505 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR6505 RNA expression–survival associations across cancer types. High MIR6505 expression shows unfavorable associations in THCA, UVM, READ and STAD, but favorable associations in KIRC and ESCA. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for MIR6505 RNA expression.
This table summarizes MIR6505 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR6505. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR6505 shows lower tumor expression in KIRC and higher tumor expression in KICH and KIRP. The KIRC box plot shows higher MIR6505 RNA expression in normal versus tumor tissue (log2 FC = −0.181, t-test p = .002).
This table shows molecular features associated with MIR6505 in patient tissues and cancer cell lines. In patient samples, MIR6505 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
